1. Home
  2. IFRX vs YAAS Comparison

IFRX vs YAAS Comparison

Compare IFRX & YAAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IFRX
  • YAAS
  • Stock Information
  • Founded
  • IFRX 2007
  • YAAS 2018
  • Country
  • IFRX Germany
  • YAAS China
  • Employees
  • IFRX N/A
  • YAAS N/A
  • Industry
  • IFRX Biotechnology: Pharmaceutical Preparations
  • YAAS Computer Software: Prepackaged Software
  • Sector
  • IFRX Health Care
  • YAAS Technology
  • Exchange
  • IFRX Nasdaq
  • YAAS Nasdaq
  • Market Cap
  • IFRX 117.8M
  • YAAS 127.2M
  • IPO Year
  • IFRX 2017
  • YAAS 2024
  • Fundamental
  • Price
  • IFRX $1.15
  • YAAS $2.26
  • Analyst Decision
  • IFRX Strong Buy
  • YAAS
  • Analyst Count
  • IFRX 1
  • YAAS 0
  • Target Price
  • IFRX $8.00
  • YAAS N/A
  • AVG Volume (30 Days)
  • IFRX 623.9K
  • YAAS 65.2K
  • Earning Date
  • IFRX 05-07-2025
  • YAAS 01-01-0001
  • Dividend Yield
  • IFRX N/A
  • YAAS N/A
  • EPS Growth
  • IFRX N/A
  • YAAS N/A
  • EPS
  • IFRX N/A
  • YAAS N/A
  • Revenue
  • IFRX $187,930.00
  • YAAS $521,240.00
  • Revenue This Year
  • IFRX $396.02
  • YAAS N/A
  • Revenue Next Year
  • IFRX $155.22
  • YAAS N/A
  • P/E Ratio
  • IFRX N/A
  • YAAS N/A
  • Revenue Growth
  • IFRX 177.12
  • YAAS N/A
  • 52 Week Low
  • IFRX $1.14
  • YAAS $1.58
  • 52 Week High
  • IFRX $2.82
  • YAAS $4.50
  • Technical
  • Relative Strength Index (RSI)
  • IFRX 24.46
  • YAAS N/A
  • Support Level
  • IFRX $1.76
  • YAAS N/A
  • Resistance Level
  • IFRX $1.34
  • YAAS N/A
  • Average True Range (ATR)
  • IFRX 0.14
  • YAAS 0.00
  • MACD
  • IFRX -0.01
  • YAAS 0.00
  • Stochastic Oscillator
  • IFRX 1.39
  • YAAS 0.00

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

About YAAS Youxin Technology Ltd Class A Ordinary shares

Youxin Technology Ltd is a SaaS and PaaS provider committed to helping retail enterprises digitally transform their businesses to develop, use and control business applications without the need to purchase complex IT infrastructure. The company leverages the technologies used to develop its PaaS platform to standardize customized customer relationship management, or CRM, services to its clients that seamlessly connect all levels of the retail chain from management teams to customers. Its products give its retail clients a comprehensive view of their business operations in real-time on multiple interfaces, allowing them to make critical business decisions anytime and anywhere.

Share on Social Networks: